TL;DR
This paper introduces a novel workflow using Cone Beam CT (CBCT) and "Prediction Ablation Volume Software" to improve the precision and effectiveness of microwave ablation for liver tumors. By creating a virtual treatment zone, the software helps interventional radiologists better plan, guide, and verify ablations, leading to higher technical success and efficacy rates.
What Problem Does This Paper Address?
Percutaneous ablation, a minimally invasive cancer treatment, faces a significant challenge in ensuring complete tumor eradication. This is due to inherent operator variability and human imperfections in targeting and verifying the ablation zone. The risk of leaving behind residual tumor cells or undertreating the lesion can lead to local progression and treatment failure. Existing imaging guidance methods, while advanced, can still struggle with precise margin assessment, especially for complex or difficult-to-visualize lesions. This paper aims to address this by evaluating a new software-assisted approach that provides a more objective and visual method for planning and verifying the ablation.
Methods
The study introduces a treatment flowchart incorporating a CBCT "Prediction Ablation Volume Software." The core of this method involves:
- Pre-procedural Imaging: Contrast-enhanced CT or MRI is used to segment the target liver lesion.
- US-Guided Antenna Positioning: The ablation probe is initially positioned using ultrasound, often with the aid of US-CT or US-MRI fusion (PercuNav software) for enhanced visualization.
- Intra-procedural CBCT Fusion: A non-contrast CBCT is acquired during the procedure. This CBCT data is then rigidly fused with the pre-procedural CT/MRI.
- Virtual Ablation Volume Prediction: The "Prediction Ablation Volume Software" (XperGuide System) uses the fused images to create a superimposed virtual representation of the expected ablation zone based on the microwave ablation system's parameters (power and time).
- Real-time Verification and Adjustment: The interventional radiologist can visually assess if the predicted ablation zone adequately covers the segmented lesion and its margin. If coverage is suboptimal, the antenna can be repositioned before ablation begins.
- Post-procedural Control: A post-ablation CBCT or US is performed to detect complications, followed by a ~1-month follow-up CT/MRI for efficacy assessment.
The key innovation lies in the real-time, intra-procedural prediction and verification of the ablation volume using CBCT fusion, allowing for proactive adjustments to the treatment plan.
Datasets
The study retrospectively analyzed data from 29 non-consecutive patients with 32 liver lesions treated between April 2021 and January 2022. These patients were part of a prospective tumor ablation registry. The data included pre-procedural CT/MRI scans, intra-procedural CBCT scans, and ~1-month follow-up CT/MRI scans.
Key Insights and Ideas
- Bridging the Gap Between Planning and Execution: The software provides a crucial bridge between the initial imaging plan and the actual ablation, allowing for immediate feedback and correction.
- Objective Margin Assessment: Moving beyond subjective visual assessment, the virtual ablation zone offers a more objective way to evaluate margin coverage.
- Proactive Problem Solving: The ability to predict and visualize the ablation zone before activating the microwave probe allows for proactive repositioning, potentially preventing undertreatment and the need for repeat procedures.
- Workflow Alteration: The implementation of this flowchart significantly altered the procedure workflow, with a notable rate of antenna repositioning, suggesting its utility in optimizing probe placement.
- Potential for Standardization: This approach has the potential to standardize the ablation process, reducing operator-dependent variability.
Key Results
- Technical Success: Achieved in 30 out of 32 liver lesions (94%).
- Technical Efficacy: 87% of treated lesions showed complete ablation at 1-month follow-up.
- Antenna Repositioning: The antenna was repositioned in 16 of 30 evaluable target lesions (53%), indicating the software's impact on treatment planning.
- Residual Tumor: Residual tumor was detected in only 4 of 30 treated lesions (13%) at follow-up.
- Procedure Time: The average procedure time was 49 minutes (range 20-120 minutes).
- Complications: Two grade II and one grade III CIRSE classification system complications were reported.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective and Non-consecutive Study: This design introduces potential biases, and the study reflects the experience of users who were already proficient with the technology.
- Sample Size: While one of the largest cohorts for this specific software, a larger prospective study with longer follow-up is needed.
- No Sample Size Calculation: The study did not pre-define a sample size.
- Cause and Effect: The design doesn't definitively prove cause and effect for probe manipulations based on the software.
- Histological Heterogeneity: The inclusion of patients with different tumor histologies may introduce inhomogeneities.
- Variability in Ablation Dimensions: The actual ablation dimensions may not always perfectly recapitulate manufacturer expectations due to various factors.
- CBCT Motion Artifacts: In two cases, respiratory motion led to CBCT motion artifacts, impacting fusion quality and causing technical failure. The authors suggest general anesthesia might mitigate this.
Future work should focus on prospective studies with larger patient cohorts and longer follow-up periods to further validate the clinical efficacy and cost-effectiveness of this CBCT-based prediction and verification tool. The authors also suggest exploring its utility as an additional tool for "Ablation Confirmation" in liver percutaneous ablation treatments.
Summary updated